Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / EDRN-WHI Pre-Clinical Colon Ca Specimens

EDRN-WHI Pre-Clinical Colon Ca Specimens


No involved investigator sites defined.

proteins, peptides,
G.I. and Other Associated Cancers Research Group

Specifically, it is proposed to assess plasma proteins from postmenopausal women diagnosed with colon cancer within a span of 18 months after year-3 OS blood draw and from appropriate matched controls enrolled in the WHI OS study. The range of case-control differences sought in plasma include: 1 Detection and identification of proteins that may be derived from tumor cells through the classical secreted protein pathway and through non-classical pathways (eg protein cleavage and release) or through cell turnover. 2 Detection and identification of protein changes associated with the host response that occur during tumor development and that may be related to inflammation, angiogenesis, infiltration of tumor with host cells and other processes. 3 Identification of tumor derived proteins that induce a humoral immune response in the form of autoantibodies that are detectable at the preclinical stage.

Specific Aims are identified by each assay laboratory.
The primary analysis for this study is to identify proteins/peptides that have potential as colon cancer early detection or risk prediction markers for subsequent validation. The secondary aim is to see if some proteins/peptides are complementary in their early detection abilities so their combinations will improve their sensitivity and specificity. Since thousands of protein/peptides will be identified and/or quantified, one important issue is to quantify and control the False Discovery Rate (# of false positive finding / # of selected markers as differentially expressed) and maintain reasonable power to detect truly differentially expressed markers. Another important feature of the data analysis is that the derived data from mass spectrometry critically depends on the algorithms of identifying the peptides, assigning protein identities and intensities. Coordinating center biostatisticians need work closely with proteomics bioinformaticians and computational biologists with expected iterations between data processing and data analyses.

There are currently no biomarkers annotated for this protocol.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.